Linked here is a detailed quantitative analysis of Abbvie Inc. (ABBV). Below are some highlights from the above linked analysis: Company Description: Abbvie Inc. is a global research-based pharmaceuticals business that emerged as a separate entity following its spin-off from Abbott Laboratories at the start of 2013. AbbVie's key drug is Humira for rheumatoid arthritis.
Peers: The company's peer group includes: Merck & Co. Inc. (MRK) with a 2.7% yield, Bristol-Myers Squibb Company (BMY) with a 3.5% yield, and Eli Lilly & Co. (LLY) with a 1.0% yield. Conclusion: ABBV earned one Star in the Fair Value section, earned two Stars in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of four Stars. This quantitatively ranks ABBV as a...
Source: Dividend Growth Stocks
Related Articles:
Dividend Growth Stocks News
- ASX Dividend Stocks To Enhance Your Portfolio - Yahoo Finance - 8/13/2025
- Why dividend stocks pay benefits in volatile markets - InvestmentNews - 8/13/2025
- Top Dividend Stocks To Consider In August 2025 - Yahoo Finance - 8/13/2025
- Top TSX Dividend Stocks To Consider In August 2025 - Yahoo Finance - 8/13/2025
- 2 Beaten Down Dividend Stocks to Buy Now and Hold at Least a Decade - MSN - 8/13/2025
- Nucor Corporation (NUE) Dividend Stock Analysis - 8/8/2025
- Raytheon Technologies Corporation (RTX) Dividend Stock Analysis - 7/31/2025
- Duke Energy (DUK) Dividend Stock Analysis - 7/25/2025
- Chevron Corporation (CVX) Dividend Stock Analysis - 7/18/2025
- Emerson Electric Co. (EMR) Dividend Stock Analysis - 7/11/2025
Abbvie Inc. (ABBV) Dividend Stock Analysis
Posted by D4L | Thursday, July 20, 2023 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.